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K Parzych1, TM Chinn1,2, Z Chen1, S Loaiza1, F Porsch1, GN Valbuena3, MF Kleijnen1, A Karadimitris1, E Gentleman2, HC Keun3 and
HW Auner*,1
The cellular mechanisms that control protein degradation may constitute a non-oncogenic cancer cell vulnerability and, therefore,
a therapeutic target. Although this proposition is supported by the clinical success of proteasome inhibitors in some malignancies,
most cancers are resistant to proteasome inhibition. The ATPase valosin-containing protein (VCP; p97) is an essential regulator of
protein degradation in multiple pathways and has emerged as a target for cancer therapy. We found that pharmacological depletion
of VCP enzymatic activity with mechanistically different inhibitors robustly induced proteotoxic stress in solid cancer and multiple
myeloma cells, including cells that were insensitive, adapted, or clinically resistant to proteasome inhibition. VCP inhibition had an
impact on two key regulators of protein synthesis, eukaryotic initiation factor 2α (eIF2α) and mechanistic target of rapamycin
complex 1 (mTORC1), and attenuated global protein synthesis. However, a block on protein translation that was itself cytotoxic
alleviated stress signaling and reduced cell death triggered by VCP inhibition. Some of the proteotoxic effects of VCP depletion
depended on the eIF2α phosphatase, protein phosphatase 1 regulatory subunit 15A (PPP1R15A)/PP1c, but not on mTORC1,
although there appeared to be cross-talk between them. Thus, cancer cell death following VCP inhibition was linked to inadequate
fine-tuning of protein synthesis and activity of PPP1R15A/PP1c. VCP inhibitors also perturbed intracellular amino acid levels,
activated eukaryotic translation initiation factor 2α kinase 4 (EIF2AK4), and enhanced cellular dependence on amino acid supplies,
consistent with a failure of amino acid homeostasis. Many of the observed effects of VCP inhibition differed from the effects
triggered by proteasome inhibition or by protein misfolding. Thus, depletion of VCP enzymatic activity triggers cancer cell death in
part through inadequate regulation of protein synthesis and amino acid metabolism. The data provide novel insights into the
maintenance of intracellular proteostasis by VCP and may have implications for the development of anti-cancer therapies.
Cell Death and Disease (2015) 6, e2031; doi:10.1038/cddis.2015.373; published online 31 December 2015
The intracellular degradation of proteins that are damaged,
misfolded, or no longer required is essential for normal cellular
function. To maintain protein homeostasis (proteostasis), cells
orchestrate a delicate balance between protein degradation
and protein synthesis. Cancer cells may have a heightened
dependence on protein degradation pathways, as their
numerous genomic mutations often effect an imbalance in
protein levels or the production of defective proteins.1,2 More-
over, cancer cells may hyperactivate pathways that control
protein synthesis, placing additional strain on the cellular
mechanisms that govern protein degradation.3,4 Therefore,
drugs that disrupt protein breakdown pathways have con-
siderable potential for anticancer therapy.
The ubiquitin–proteasome system (UPS) is the major
mechanism in eukaryotic cells by which cytosolic, nuclear,
and endoplasmic reticulum (ER)-derived proteins are de-
graded.5 Cells maintain physiological protein levels and an
adequate intracellular amino acid pool by balancing protein
synthesis with the activity of the UPS, and that of proteasome-
independent degradation pathways.6,7 The clinical use of
proteasome inhibitors in multiple myeloma (MM) and mantle
cell lymphoma has demonstrated that it is in principle possible
to disrupt protein degradation in the UPS with fatal con-
sequences for cancer cells, while largely sparing healthy cells.
However, proteasome inhibitors are largely ineffective in other
cancers.
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VCP (valosin-containing protein; also known as p97) is an
abundant ATPase that is conserved across all eukaryotes and
is essential for life in budding yeast and mice.8–11 VCP has the
ability to use the energy derived from ATP hydrolysis to unfold
client proteins, or to extract them from cellular structures. This
allows VCP to engage in a range of cellular processes, but its
role is best understood in the context of ER-associated
degradation (ERAD).12–19 As a key component of ERAD, VCP
mediates the extraction of misfolded proteins across the ER
membrane and their delivery to the proteasome.20–22 How-
ever, VCP has also been linked to the proteasome-indepen-
dent handling of protein aggregates and autophagy.23–28
Moreover, VCP has been implicated in proteasome recovery
after proteasome inhibition, which may underlie the resistance
of some cancers to proteasome inhibitors.29–31 Thus, VCP is
fundamental for proteostasis. This broad involvement of VCP
in intracellular protein turnover, combined with observations of
aberrant VCP expression in different cancers,32–40 suggests
that VCP inhibitors may overcome some limitations of
proteasome inhibitors by affecting multiple proteostatic mech-
anisms simultaneously. Indeed, VCP-targeting compounds
activate caspases and have an impact on both ubiquitin-de-
pendent and autophagic pathways in cancer cells in vitro and
in vivo.27,41,42 In contrast, primary rat hepatocytes and mouse
skeletal muscle cells do not undergo apoptosis on VCP
depletion and non-malignant human cells appear to be less
susceptible to VCP inhibition than cancer cells.27,43,44 Phase I
clinical trials of one VCP inhibitor are currently underway
in patients with advanced solid cancers and relapsed/
refractory myeloma (https://clinicaltrials.gov, NCT02243917
and NCT02223598). However, the mechanisms by which
pharmacological VCP depletion induces cancer cell death,
and how they differ from those mediated by proteasome
inhibition, remain incompletely understood.
ER stress is potentially fatal to cells and can be brought
about by various insults to the ER, such as the accumulation of
misfolded proteins. It is linked to a diverse range of illnesses
and is thought to be a key mechanism by which proteasome
inhibitors effect their toxicity in MM cells.45 Cells normally re-
spond to ER stress by activating the unfolded protein response
(UPR), which comprises a number of cellular adaptations that
aim to restore protein homeostasis.46 Phosphorylation of
eukaryotic initiation factor 2α (eIF2α) on a single serine is
central to one arm of the UPR and rebalances proteostasis by
temporarily attenuating global messenger RNA (mRNA) tra-
nslation.47 However, as a prolonged decrease in protein
translation would prove fatal, phosphorylation of eIF2α also
simultaneously triggers a negative feedback loop that pro-
motes protein synthesis. This feedback loop begins with the
preferential translation of the transcription factor activating
transcription factor 4 (ATF4), which induces CCAAT/
enhancer-binding proteins homologous protein (CHOP;
encoded by the DNA damage-inducible transcript 3 (DDIT3)
gene), another transcription factor. Both ATF4 and CHOP
promote the expression of protein phosphatase 1 regulatory
subunit 15A (PPP1R15A; also known as growth arrest and
DNA damage-inducible protein, GADD34), the regulatory
subunit of a stress-induced phosphatase that consists of
PPP1R15A and PP1c. PPP1R15A/PP1c dephosphorylates
eIF2α to reinstate physiological protein synthesis following the
resolution of ER stress.48–54 However, in cells with unresolved
ER stress this process generates oxidative stress and
contributes to cell death.51,53,54 Thus, the eIF2α-ATF4/
CHOP–PPP1R15A/PP1c feedback loop finely tunes protein
synthesis to regulate cell viability under conditions of protein
folding stress. eIF2α is also central to signaling networks that
integrate oxidative stress and nutrient availability with other
translation regulators such asmechanistic target of rapamycin
complex 1 (mTORC1).55,56
Here we studied the role of VCP in maintaining cancer cell
proteostasis by using compounds that inhibit VCP enzymatic
activity by different mechanisms.27,42 We show that pharma-
cological depletion of VCP kills cancer cells of diverse tissue
origins through mechanisms that regulate protein synthesis
and amino acid homeostasis. Moreover, we demonstrate that
the effects of VCP inhibition differ markedly from the effects of
proteasome inhibition. The data provide previously unrecog-
nized biological insights into the cellular mechanisms bywhich
VCP governs proteostasis and may have important implica-
tions for the development of anticancer therapies.
Results
VCP inhibitors kill cancer cells independently of their
tissue origins and sensitivity to proteasome inhibition.
We first examined the effects of VCP inhibition by directly
comparing the ability of the VCP inhibitors N2,N4-dibenzyl-
quinazoline-2,4-diamine (DBeQ)27 and Nerviano Medical
Sciences-873 (NMS-873)42 with that of the proteasome
inhibitor bortezomib, to kill a range of solid cancer and MM
cell lines, as well as primary MM cells. We chose these two
VCP-targeting compounds based on their extensive char-
acterization and mechanistic difference. The quinazoline
DBeQ is an ATP competitive VCP inhibitor, whereas
NMS-873 is a non-ATP-competitive allosteric inhibitor of
VCP.1,27,42 Both inhibitors rapidly turn off VCP enzymatic
activity and thereby avoid potential limitations of genetic
targeting related to slow or incomplete depletion of the abundant
VCP.1,57 As expected, a 24-h treatment with bortezomib
effectively killed the OPM-2, Roswell Park Memorial Institute
(RPMI)-8226, and H929 MM cell lines at an IC50 of ~ 5–10 nM
(Figure 1a and Supplementary Table S1). However, bortezomib
in concentrations up to 50 nM had a limited or no impact on
the viability of A549 lung cancer cells, Saos-2 osteosarcoma
cells, and bortezomib-adapted AMO1-Btz MM cells. In contrast,
DBeQ and NMS-873 killed all cell lines tested within a narrow
range of IC50 levels. The moderate differences in IC50s and in
the level of cell death at 24 h that we observed can probably
be explained by differences in the potency and efficacy of
DBeQ and NMS-873 (Figure 1a and Supplementary Table
S1).1,27,42 We also found that DBeQ- and NMS-873-induced
cell death largely amounted to caspase-dependent apoptotic
death (Supplementary Figure S1). Importantly, both inhibitors
also killed primary bone marrow-derived MM cells from a
patient with clinically bortezomib-resistant MM at concentra-
tions similar to those that were effective in cell lines
(Supplementary Table S1). Thus, an ATP-competitive and
an allosteric VCP inhibitor effectively kill cancer cell lines of
different tissue origins, including bortezomib-adapted and
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clinically bortezomib-resistant cells. The data suggest that
the effects of VCP inhibitors have different mechanisms of
action from proteasome inhibitors, and that their effects are
not limited to cancer cells with a distinctive secretory load,
such as MM cells.
VCP inhibition activates eIF2α signaling and upregulates
expression of its downstream targets. To investigate the
role of eIF2α-ATF4/CHOP–PPP1R15A/PP1c signaling
following VCP inhibition, we first examined the effects of
DBeQ and NMS-873 on eIF2α phosphorylation. We found
that both DBeQ and NMS-873 caused time- and dose-
dependent phosphorylation of eIF2α (Figure 1b). Treatment
with 15 μM DBeQ also resulted in a decrease in eIF2α
phosphorylation at 24 h compared with 4 h, possibly reflect-
ing its dephosphorylation by PPP1R15A (Supplementary
Figure S2). In contrast, bortezomib did not have a noticeable
effect on eIF2α phosphorylation. However, bortezomib did
BortezomibDBeQ NMS-873
OPM-2
RPMI-8226
H929
AMO1-Btz
Saos-2
A549
150
50
100
150
50
100
150
50
100
0 1 10 100μM 0 1 10 100μM 0 1 10 100nM
000
35 kDa
35 kDa
h24424424 h4244244244
2.5 5 5 μg/mL10 20 nM
TmBtzDBeQ
co
nt
ro
l  
co
nt
ro
l  
15 μM
4 24 4 24 4 24 h
2.5 5 10 μM
co
nt
ro
l  
NMS-873
p-eIF2 α
eIF2 α
ce
ll 
vi
ab
ili
ty
(%
 o
f c
on
tro
l)
Figure 1 VCP inhibitors kill multiple myeloma and solid cancer cells and induce eIF2α signaling. (a) Viability of cancer cell lines after treatment with DBeQ, NMS-873, or
bortezomib (Btz) for 24 h relative to untreated control cells. (b) Representative immunoblots with antibodies against phosphorylated (Serine 51) and total eIF2α on whole-cell
extracts from A549 cells treated with DBeQ, NMS-873, bortezomib (Btz), or tunicamycin (Tm) as indicated. Treatment with 15 μM NMS-873 for 24 h resulted in a protein yield that
was too low for immunoblot analysis (not shown). (c)mRNA levels of the indicated eIF2α-regulated genes relative to control cells (white bars; solvent treated) determined by real-
time quantitative PCR. The indicated lung cancer (A549), multiple myeloma (OPM-2), and osteosarcoma (Saos-2) cell lines were treated with DBeQ (5, 10, and 15 μM), NMS-873
(5, 10, and 15 μM), bortezomib (Btz, 20 nM), or tunicamycin (Tm, 5 μg/ml) for 16 h. Data shown are the mean± S.E.M. from three independent experiments
VCP and cancer proteostasis
K Parzych et al
3
Cell Death and Disease
cause intracellular accumulation of ubiquitinated proteins in
A549 and OPM-2 cells, confirming that it was disrupting the
UPS at the concentration used (Supplementary Figure S3).
By comparison, tunicamycin, which induces ER stress by
blocking N-linked glycosylation of ER-resident proteins,
caused eIF2α phosphorylation after both 4 and 24 h
(Figure 1b).
We next examined the effects of VCP and proteasome
inhibition on key targets downstream of eIF2α. Using real-time
quantitative PCR, we found that DBeQ and NMS-873
upregulated CHOP, ATF4, and PPP1R15A mRNA levels in a
largely dose-dependent manner (Figure 1c). Consistent with
its effect on cell death and eIF2α phosphorylation, NMS-873
appeared to be slightly more potent thanDBeQ.We also found
that the extent to which these genes were induced was largely
comparable between lung cancer, osteosarcoma, and mye-
loma cells, although some differences between cell lines could
be noted. In contrast to the VCP inhibitors, bortezomib had
only a minimal effect on PPP1R15A expression in all three cell
lines tested and a minor effect on CHOP expression in Saos-2
cells (Figure 1c). By comparison, tunicamycin upregulated
CHOP and ATF4 mRNA levels to a similar extent as the VCP
inhibitors, but its effect on PPP1R15A expression was
minimal. Both DBeQ and NMS-873 also increased CHOP
and PPP1R15A protein levels, with NMS-873 again appearing
more potent (Supplementary Figure S2). We then tested the
ability of VCP inhibitors to induce eIF2α targets in bortezomib-
adapted AMO1-Btz cells (Supplementary Figure S4). We
found that NMS-873 and DBeQ strongly induced CHOP and
PPP1R15A mRNA expression, and that NMS-873 also
upregulated ATF4, similar to what we observed in A549,
Saos-2, and OPM-2 cells. In contrast, bortezomib had no
discernible effect and the effects of tunicamycin were limited.
When misfolded proteins accumulate in the ER, cells
respond by creating more luminal chaperone proteins to as-
sist in protein folding. This process is regulated by an
alternative arm of the UPR from that involving eIF2α
phosphorylation.46 To test whether VCP inhibitors also
induced ER chaperones, we analyzed mRNA levels of binding
immunoglobulin protein (BIP) and P58IPK, and found both to
be largely upregulated in all three cell lines tested
(Supplementary Figure S5). In line with our findings on
eIF2α targets, NMS-873 had a greater effect on the transcrip-
tional induction of BIP and P58IPK than DBeQ. Although
tunicamycin also induced BIP and P58IPK, bortezomib had
little effect. Finally, we tested whether VCP inhibitor-induced
cell death correlated with the steady-state baseline expression
of VCP, ATF4, CHOP, PPP1R15A, or BIP mRNAs in the
cancer cell lines investigated and found no significant
correlation (Supplementary Figure S6).
Taken together, these findings show pronounced effects of
VCP inhibitors on the eIF2α-ATF4/CHOP-PPP1R15A/PP1c
pathway and ER chaperones. Moreover, signaling down-
stream of eIF2α in response to VCP inhibitors appeared
unaffected in bortezomib-adapted cells that show a blunted
response to proteasome inhibition and ER stress. Our
observations also demonstrate that the effects of DBeQ and
NMS-873 on pathways employed by the UPR differ from those
induced by bortezomib or tunicamycin, suggesting that VCP
inhibition triggers a distinctive type of proteotoxic stress.
Protein synthesis and PPP1R15A/PP1c-mediated eIF2α
dephosphorylation modulate proteotoxic effects of VCP
inhibition. Protein synthesis can lead to cell death under
conditions of ER stress.54 However, cells require controlled
protein translation for normal function. This led us to investi-
gate the role of protein synthesis following VCP inhibition,
making use of the translation inhibitor cycloheximide.
Immunoblotting for newly synthesized puromycinylated pro-
teins demonstrated that a 8 h treatment with cycloheximide
largely abrogated protein synthesis, as expected. Our analy-
sis also revealed that VCP inhibition triggered a considerable
reduction in global protein translation (Figure 2a), a finding
that is compatible with the phosphorylation of eIF2α we
observed. We then determined that cycloheximide treat-
ment resulted in cell death in a small proportion of cells
(Figure 2b). However, translation inhibition with cyclohex-
imide partially rescued DBeQ- and NMS-873-induced cell
death. Moreover, cycloheximide rescue was associated with
reduced induction of CHOP and BIP (Figure 2c). Thus, a
block on protein synthesis that is itself cytotoxic has a
cytoprotective effect on cells treated with VCP inhibitors that
correlates with signs of reduced proteotoxic stress.
These data led us to examine whether the effects of
VCP inhibition are modulated by the eIF2α phosphatase
PPP1R15A/PP1c.48,49 To this end we made use of the small
molecule guanabenz, which selectively inhibits stress-
induced dephosphorylation of eIF2α by PPP1R15A/PP1c.58
We first confirmed that treatment with guanabenz resulted in
the expected increase in the level of eIF2α phosphorylation
following VCP inhibition (Figure 3a). As expected, guanabenz
largely increased expression ofCHOP, ATF4, and PPP1R15A
in DBeQ-treated cells but did not appear to affect expression
levels of these genes in unstressed cells (Supplementary
Figure S7). Next, we determined that DBeQ-induced cell
death was indeed significantly attenuated in guanabenz-
treated cells (Figure 3b), indicating that PPP1R15A/PP1c
activity partly regulates cell death in response to VCP
inhibition.
Considering its role as a regulator of protein synthesis,
we then tested whether mTORC1 might be affected by
PPP1R15A/PP1c. We found that DBeQ alone caused a
moderate reduction in ribosomal protein S6 phosphorylation, a
readout for mTORC1 activity (Figure 3c).6,59 We also
observed that co-treatment with guanabenz mildly enhanced
the DBeQ-induced reduction of S6 phosphorylation. Thus,
inhibition of PPP1R15A/PP1c-mediated eIF2α dephosphor-
ylation by guanabenz decreases cell death and enhances
attenuation of mTORC1 signaling following VCP inhibition.
We then tested whether inhibition of mTORC1 activity with
rapamycin had an impact on eIF2α phosphorylation and the
proteotoxic effects of VCP depletion. Indicating its inhibitory
effect on mTORC1, rapamycin remarkably reduced phosphor-
ylation of S6 in unstressed A459 cells and appeared to mildly
enhance the reduction of S6 phosphorylation in cells treated
with DBeQ (Figure 3d). Rapamycin also increased eIF2α
phosphorylation both in unstressed and DBeQ-treated cells,
although the effect appeared moderate (Figure 3d). Moreover,
rapamycin appeared to increase mRNA levels of CHOP and
PPP1R15A, in line with its effects on eIF2α phosphorylation
(Figure 3e). Comparable results on the effects of rapamycin on
VCP and cancer proteostasis
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eIF2α phosphorylation and gene expression were observed in
OPM-2 cells treated with NMS-873 (not shown). Importantly,
rapamycin had no effect on the viability of cells treated with
either DBeQ or NMS-873 (Figure 3f). Thus, VCP inhibition has
an impact on two important cellular regulators of protein
synthesis, eIF2α and mTORC1, and there appears to be
cross-talk between them; however, mTORC1 does not affect
cell viability following VCP inhibition.
VCP inhibition disrupts intracellular amino acid home-
ostasis. To maintain intracellular amino acid homeostasis,
cells tightly co-ordinate protein synthesis with degradation.6
Proteasome inhibition has been reported to reduce intracel-
lular amino acids levels;60,61 however, the effects of VCP
inhibitors on amino acid homeostasis have not been studied.
To address this gap in knowledge, we performed unsuper-
vised gas chromatography–mass spectrometry (GC-MS) of
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extracts from A549 cells treated with DBeQ or NMS-873 and
compared their effects with that of bortezomib (Figure 4 and
Supplementary Table S2). Bortezomib decreased intracellu-
lar levels of numerous amino acids, consistent with previous
reports.6,60,61 However, VCP inhibitors had a different and
more complex effect. Although both DBeQ and NMS-873
caused a significant decrease of β-alanine and hypotaurine
levels, treatment with NMS-873 also decreased levels of
asparagine, aspartic acid, and N-acetyl aspartic acid.
Surprisingly, treatment with NMS-873 significantly increased
the levels of four other amino acids: glutamic acid, phenyla-
lanine, serine, and tyrosine. DBeQ appeared to increase the
levels of three of these four amino acids, and those of several
others, but the differences were not statistically significant
compared with untreated cells (Supplementary Table S2).
Although DBeQ and NMS-873 caused changes in intracel-
lular amino acid levels that were largely comparable with
each other, a larger number of statistically significant
changes were observed after NMS-873 treatment, which
may be explained by its higher potency. Thus, pharmacolo-
gical depletion of VCP enzymatic activity elicits a complex
effect on intracellular amino acid pools.
We next asked whether the effect of VCP inhibition on
amino acid levels was functionally relevant to cells. To test this,
we first examined activation of eukaryotic translation initiation
factor 2α kinase (EIF2AK4; general control nonderepressible 2
(GCN2)), an eIF2α kinase primarily activated by amino acid
deprivation.62–64 Indeed, immunoblots on extracts from A549
cells treated with DBeQ and NMS-873 showed phosphoryla-
tion of EIF2AK4 at Threonine 889, indicating its activation. In
contrast, neither bortezomib nor tunicamycin appeared to
trigger phosphorylation of EIF2AK4 (Figure 5a).
We then hypothesized that putting an additional strain on
amino acid metabolism would enhance the toxicity of VCP
inhibitors if their effects on amino acid levels were functionally
relevant. Indeed, when we depleted three amino acids
(L-methionine, L-cystine, and L-glutamine) from the cell culture
medium, we observed increased cell death on treatment with
DBeQ and NMS-873 (Figures 5b and c). Moreover, we
observed that amino acid depletion enhanced the VCP
inhibitor-mediated induction of CHOP and PPP1R15A
(Figure 5d). However, amino acid depletion affected neither
viability nor CHOP/PPP1R15A expression in unstressed
cells or in cells treated with tunicamycin (Figure 5d and
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Supplementary Figure S8). Thus, VCP inhibitors disrupt
intracellular amino acid homeostasis and enhance cellular
dependence on amino acid supplies.
Discussion
Phosphorylation of the translation initiation factor eIF2α can
promote cell survival under acute stress conditions by
attenuating protein translation. However, eIF2α phosphoryla-
tion can also mediate death in cells with unresolved stress by
promoting protein synthesis.46,54 We found that VCP inhibitors
consistently and strongly activated eIF2α signaling in cancer
cells derived from different tissues, including proteasome
inhibitor-adapted myeloma cells. This finding led us to
investigate the role of major protein translation control path-
ways in VCP inhibitor-induced cell death. We found that a
block on protein translation, which was toxic on its own, was
cytoprotective in cells in which VCP was inhibited. How could
protein synthesis have a detrimental impact on cells? The
effect might be explained by a reduced cellular dependence on
protein quality control mechanisms that depend on VCP, such
as ERAD, when protein synthesis is reduced. Protein
synthesis under conditions of VCP inhibition could also result
in higher level of reactive oxygen species or loss of ATP.54
Intriguingly, protein synthesis was attenuated in response to
VCP inhibition, probably as part of the proteotoxic stress
response. Therefore, our data suggest that either the extent or
nature of this downregulation was inadequate for optimal
cytoprotection. This finding highlights the requirement for cells
to precisely fine-tune protein synthesis under conditions of
proteotoxic stress.
Our observations also indicate that VCP and PPP1R15A/
PP1c have an impact on the mTORC1 pathway, although it
remains to be established how these effects are mediated.
Moreover, we found that pharmacological inhibition of
mTORC1 had an impact on eIF2α and its downstream targets.
These data are important, as they show that at least two key
cellular signaling hubs that regulate protein synthesis, eIF2α
and mTORC1, are affected by VCP inhibition, and that
there is cross-talk between them, thereby adding to the
growing literature on the interactions between eIF2α and
mTORC1.55,64–67 However, only guanabenz, but not rapamy-
cin, had a cytoprotective effect following VCP inhibition. This
may be explained by feedback effects of mTORC1 inhibition
on the PI3K/Akt pathway and mTORC2, or effects on
autophagy, which is also modulated by VCP.27,42,55,64 The
findings may be clinically relevant, as some approaches to
improve cancer therapy aim to reduce the activity of pathways
that promote protein synthesis, such as mTORC1.68 Our
results suggest that such a strategy may not be beneficial
when combined with proteotoxic treatment approaches such
as VCP inhibition.
The effects of VCP inhibitors on mTORC1, which also
responds to amino acid shortage, led us to investigate their
effects on intracellular amino acid homeostasis. We found that
VCP inhibitors triggered both decreases and increases in
individual intracellular amino acid levels. In contrast, and in
line with previous reports, we found that proteasome inhibition
resulted in a substantial decrease in the intracellular levels of
many amino acids6,60 The unexpected impact of VCP
inhibition on amino acid levels might be related to the VCP
inhibitors’ complex effects on the regulation of protein
synthesis and thus amino acid utilization. Given that DBeQ
and NMS-873 promoted phosphorylation of EIF2AK4, a major
eIF2α kinase that senses amino acid shortages,62 the
complex effects on amino acid homeostasis elicited by VCP
inhibitors are likely to be functionally relevant. In contrast,
bortezomib did not induce EIF2AK4 phosphorylation and was
less effective than the VCP inhibitors in inducing cell death,
suggesting that the cells activated mechanisms that at least
Figure 4 Inhibitors of VCP and the proteasome have different effects on intracellular amino acid levels. Relative levels of intracellular amino acids determined by GC-MS.
A549 cell extracts were prepared as described in Materials and Methods after treatment with DBeQ (10 μM), NMS-873 (10 μM), or bortezomib (20 nM) for 8 h. Data shown are
the mean± S.E.M. relative to untreated (control) cells from four independent experiments
VCP and cancer proteostasis
K Parzych et al
7
Cell Death and Disease
partly compensated for the reduction in amino acid levels
triggered by proteasome inhibition.
We noted that EIF2AK4 phosphorylation occurred quite
some time after the changes in mTORC1 activity and eIF2α
phosphorylation. As such, the precise mechanisms and
kinetics by which VCP inhibition leads to EIF2AK4 activation
remain to be established. Moreover, it is still unclear whether
EIF2AK4 or the ER stress sensor EIF2AK3 protein kinase
R (PKR)-like endoplasmic reticulum kinase is the predominant
eIF2α kinase after VCP inhibition or, indeed, whether both
have a role.
We also found that the toxic effects of VCP inhibition were
enhanced when extrinsic amino acid supplies were limited,
whereas the same amino acid limitation had no measurable
effect on unstressed cell or cells undergoing protein misfolding
stress. Given that tumours may be hyperdependent on
nutrient supplies and may scavenge extracellular protein to
ensure sufficient amino acid availability,69 the VCP inhibitor-
associated heightened dependence on amino acid supplies
may be clinically relevant. Taken together, our data provide
evidence that VCP inhibitors induce a functionally detrimental
disruption of intracellular amino acid homeostasis.
In summary (Figure 6), we demonstrate that compounds
that target VCP enzymatic activity disrupt multiple aspects of
intracellular protein metabolism. These findings advance our
understanding of howVCPmaintains proteostasis andmay be
relevant for the clinical development of VCP inhibitors for
cancer therapy.
Materials and Methods
Cells and reagents. The human MM cell lines OPM-2, H929, and RPMI-8226
were purchased from the Deutsche Sammlung von Mikroorganismen und
Zellkulturen GmbH (Braunschweig, Germany). Saos-2 cells were from the
European Collection of Cell Cultures (Salisbury, UK). A549 cells were a gift from
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Figure 5 VCP inhibitors disrupt intracellular amino acid homeostasis. (a) VCP inhibitors trigger EIF2AK4 phosphorylation. Representative immunoblots with antibodies
against phosphorylated (Thr889) and total EIF2AK4 (GCN2) on whole-cell extracts from A549 cells treated with DBeQ, NMS-873, bortezomib (Btz), or tunicamycin (Tm). (b) Cell
viability of A549 and OPM-2 cells growing in complete media (+AA) or media deficient in L-glutamine, L-methionine, and L-cystine (–AA). Cells were treated with DBeQ (15 μM for
A549 cells and 10 μM for OPM2 cells) or NMS-873 (10 μM for A549 cells and 5 μM for OPM-2 cells) for 16 h. (c) Representative images of A549 cells treated as in (b). Images
shown were taken with an ECOS core digital microscope at × 100 magnification (size bar: 25 μm). (d) mRNA levels of the indicated genes relative to untreated controls
determined by real-time quantitative PCR after treatment of A549 cells as described in (b). Data shown in (b) and (d) are the mean± S.E.M. from three independent experiments.
*Po0.05, **Po0.01, ***Po0.001
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Jane Mitchell (Imperial College London, London, UK). Cell culture identity was
verified by short tandem repeat profiling provided by the University of Sheffield, UK
(not shown). Bortezomib-adapted AMO-1 cells were a gift from Christoph Driessen
(Kantonsspital St. Gallen) and have been described before.70,71 Cell lines were
regularly tested for mycoplasma contamination using the MycoAlert Mycoplasma
Detection Kit (Lonza, Cambridge, UK). Primary human myeloma cells were isolated
from a diagnostic bone marrow aspirate performed on a patient with relapsed
MM by CD138 magnetic bead selection under appropriate research ethics
committee approval (REC reference 11/H0308/9) at Imperial College Healthcare
NHS Trust. The cells were isolated shortly before initiation of treatment with a
regimen consisting of bortezomib, cyclophosphamide, and dexamethasone, to
which the patient subsequently proved to be clinically resistant. Cells were grown in
RPMI (myeloma cells) or Dulbecco’s modified Eagle’s medium (DMEM; Saos-2,
A549 cells) media (Sigma-Aldrich, St. Louis, MO, USA) supplemented with
10% fetal bovine serum (FBS) and penicillin plus streptomycin. For experiments on
amino acid depletion we compared DMEM and RPMI containing amino acids
(Sigma-Aldrich; D1145, R8758) with DMEM and RPMI without L-methionine,
L-cystine, and L-glutamine (Sigma-Aldrich; D0422, R7513), both supplemented
with 10% dialyzed FBS (Sigma-Aldrich; F0392). DBeQ (Biovision, Milpitas, CA,
USA), NMS-873 (Sigma-Aldrich), bortezomib (Sigma-Aldrich), tunicamycin
(Sigma-Aldrich), guanabenz (Sigma-Aldrich), rapamycin (Sigma-Aldrich), cyclohex-
imide (Sigma-Aldrich) and Z-VAD-FMK (Tocris Bioscience, Bristol, UK) were
dissolved in dimethylsulfoxide and stored at − 20 °C.
Cell viability. Cell viability was measured using the AlamarBlue cell viability
reagent (Thermo Fisher, Waltham, MA, USA) according to the manufacturer’s
instructions. Briefly, cells were grown in 96-well plates, AlamarBlue was added at
1/10 of the culture volume at the end of the indicated experimental treatment times,
and the fluorescence read at an emission wavelength of 590 nm following excitation
at 544 nm. Apoptosis was determined by flow cytometric analysis of Annexin
V-FITC and propidium iodide-stained cells (BD Biosciences, San Jose, CA, USA).
All results were obtained from three independent experiments, each consisting of
three technical replicates. Results are shown as mean viability relative to untreated
or vehicle (solvent)-treated cells.
mRNA expression analysis by real-time PCR. Cells were collected
and snap frozen using liquid nitrogen. RNA was extracted using the GeneJET RNA
Purification Kit (Thermo Fisher) followed by removal of genomic DNA according to
the manufacturer’s instructions. cDNA synthesis was performed using the RevertAid
First Strand cDNA Synthesis Kit (Thermo Fisher) according to the manufacturer’s
instructions using an Applied Biosystems 2720 Thermal Cycler (Life Technologies,
Carlsbad, CA, USA). PCR reactions were performed on an Applied Biosystems
StepOnePlus machine (Applied Biosystems, Foster City, CA, USA) using 10 μl
SYBR Green JumpStart Taq ready Mix (Sigma-Aldrich), 0.3 μM sequence-specific
primers, and 25 ng cDNA under standard conditions.
Immunoblotting. Whole-cell protein extracts were prepared on ice using a
lysis buffer containing 50 mM HEPES (N-2-hydroxyethylpiperazine-N′-2-ethanesul-
fonic acid) pH 7.5, 50 mM NaF, 5 mM Na pyrophosphate, 1 mM EDTA, 1 mM
dithiothreitol, 10% glycerol, 1% Triton, and Complete EDTA-free Protease Inhibitor
Cocktail (Roche, Basel, Switzerland). Primary antibodies used were as follows:
phospho-GCN2 Thr889 (Abcam, Cambridge, UK), GCN2 (Cell Signalling
Technology, Danvers, MA, USA), GADD34/PPP1R15A (Santa Cruz Biotechnology,
Dallas, TX, USA), phospho-eIF2α Ser51 (Cell Signalling Technology), eIF2α
(Cell Signalling Technology), β-tubulin (Cell Signalling Technology), S6 ribosomal
protein 5G10 (Cell Signalling Technology), and phospho-S6 ribosomal protein
Ser235/236 (Cell Signalling Technology). The PageRuler Plus Prestained Protein
Ladder (Thermo Fisher) was used as a molecular weight marker.
GC-MS of intracellular amino acids. Intracellular metabolites were
extracted from cultured cells by cold methanol quenching. Aqueous metabolites
were separated from the intracellular extract using a 2 : 1 : 3 chloroform:methanol:
water extraction method. The aqueous portion of the extract was separated and
lyophilized in silanized 1.5 ml glass vials before analysis. Derivatization for GC-MS
was carried out by methoximation followed by trimethylsilylation according to the
protocol described by Kind et al.72 Samples were analyzed on an Agilent 7890 gas
chromatograph (Agilent Technologies, Santa Clara, CA, USA) connected to an
Agilent 5975 MSD (Agilent Technologies) using the FiehnLib settings72 and
retention time-locking to myristic acid-d27. GC-MS data were processed by
deconvolution using AMDIS using the Fiehn library, followed by integration using
GaVIN73 based on the quantification ion for each metabolite as taken from the Fiehn
library. Data were normalized to cell number and statistical analyses were carried
out in the R statistical environment.
Analysis of protein synthesis by puromycin labeling. Semi-
quantitative monitoring of protein synthesis was carried out based on the previously
described SUnSET method.74 Briefly, newly synthesized peptides were labeled in
cultured cells by the addition of puromycin (InvivoGen, San Diego, CA, USA);
5 μg/ml for 10 min before cells were collected and whole-cell extracts were
prepared for immunoblotting as described above, using anti-puromycin
antibody clone 12D10 (Merck Millipore, Darmstadt, Germany) and anti-mouse
IgG-HRP-linked antibody (Cell Signalling Technology).
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Statistical analysis. Unless stated otherwise, data show means and S.E.M.
from three independent experiments. Analysis of variance and Bonferroni
posttests were used for comparisons between treatment groups. Correlation
between cell viability loss after inhibitor treatment and baseline gene expres-
sion was analyzed using Pearson’s correlation coefficient (r). T-test was used to
establish correlation coefficient significance. Calculations were done using
GraphPad PRISM Version 6.05 (GraphPad Software, La Jolla, CA, USA).
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